| |
Maturation Inhibitor Bevirimat,
now called MPC-4326, Starting Phase 2b in 2nd Half 2009
|
| |
| |
Myriad Pharma purchased the rights from Panacos for bevirimat, the first maturstion inhibitor. And Myriad is planning a phase 2 study to examine efficacy and safety for bevirimat in the 2nd half of 2009. At the 2008 Resistance Workshop last summer Panacos reported that study patients with certain identified pre-existing polymorphisms did not respond well to bevirimat with hardly any viral load reduction but patients without these polymorphisms achieved on average a 1.24 viral load reduction. Development was stalled but now bevirimat development by Myriad is moving ahead. Myriad is researching the development of a genotypic algorithm to predict response building on the research started by Panacos, below is a link to the polymorphism-response data presented at the Resistance Workshop in Sitges last year.
HIV-1 Gag Polymorphisms Determine Treatment Response to Bevirimat ...
Optimal bevirimat treatment response requires plasma trough >20 ug/mL and lack of Gag polymorphisms at positions 369, 370 or 371 ...
www.natap.org/2008/ResisWksp/ResisWksp_23.htm
Myriad Pharmaceuticals Acquires Novel HIV Drug, Bevirimat ...
Jan 21, 2009 ... Myriad Pharmaceuticals Acquires Novel HIV Drug, Bevirimat, a First-in-Class Maturation Inhibitor, Represents a New Class of HIV Drugs ...
www.natap.org/2009/newsUpdates/012209_01.htm
Panacos Announces Discovery of Bevirimat Patient Response Predictors
Patients who had the predictors of response and effective bevirimat target blood levels had a mean viral load reduction of 1.26 log10. ...
www.natap.org/2008/newsUpdates/030508_01.htm
|
|
| |
| |
|
|
|
